Explore FLT3/CD135/FLT-3 gene products and cross-species
research data at TarMart platform. Discover comprehensive
biological information, expression tools, and therapeutic
insights for Homo sapiens (human), Cynomolgus monkeys, rodents
(mouse/rat), canines, felines, bovines, and equines. Your
premier destination for multi-species gene research solutions
Target
sublocation: Transmembrane Protein.
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia. [provided by RefSeq, Jan 2015]
| Target ID |
GM-T74312
|
| Target Name |
FLT3/CD135/FLT-3
|
Gene Group ldentifer
（Target Gene ID in Homo
species)
|
2322
|
| Gene ID |
100061780 (Equus caballus), 101099264 (Felis catus), 140635 (Rattus norvegicus), 14255 (Mus musculus)
2322 (Homo sapiens), 486025 (Canis lupus familiaris), 512700 (Bos taurus), 721712 (Macaca mulatta)
|
| Target Alternative Names |
B230315G04,CD135,FL cytokine receptor,FLK-2,FLK2,FLT-3,FLT3,Fetal liver kinase-2 (FLK-2),Flk-2,Flk2,Flt-3,Flt3,Fms-like tyrosine kinase 3 (FLT-3),Ly72,Receptor-type tyrosine-protein kinase FLT3,STK1,Stem cell tyrosine kinase 1 (STK-1),wmfl
|
| Uniprot Accession |
Q00342,P36888
|
| Protein Sub-location |
Transmembrane Protein
|
| Category |
Therapeutics Target, Immuno-oncology Target
|
| Disease |
cancer
|
| Disease from KEGG |
MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Acute myeloid leukemia, Central carbon metabolism in cancer
|
| Gene Ensembl |
ENSECAG00000002171, ENSMUSG00000042817, ENSG00000122025, ENSCAFG00845024412, ENSBTAG00000018572, ENSMMUG00000016139
|
| Target Classification |
Kinase, Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA)
|
Pre-made viral vector of FLT3/CD135/FLT-3 cDNA Clones/ORF Plasmid
FLT3/CD135/FLT-3 siRNA/miRNA/oligo for RNA interfence (RNAi)
| Cat No. | Product Name | GeneID | Species | Grade | Detail |
|---|
| pGMoligo2322 | Pre-made Human FLT3/FLK2/STK1 siRNA oligo Duplex | 2322 | Human | In-vitro grade; in-vivo grade | Detail |
| pGMoligo140635 | Pre-made Rat Flt3 siRNA oligo Duplex | 140635 | Rat | In-vitro grade; in-vivo grade | Detail |
| pGMoligo14255 | Pre-made Mouse Flt3/Flk2/Ly72 siRNA oligo Duplex | 14255 | Mouse | In-vitro grade; in-vivo grade | Detail |
| pGMoligo721712 | Pre-made Cynomolgus/Rhesus macaque FLT3 siRNA oligo Duplex | 721712 | Cynomolgus/Rhesus macaque | In-vitro grade; in-vivo grade | Detail |
| pGMoligo101099264 | Pre-made Cat/Feline FLT3 siRNA oligo Duplex | 101099264 | Cat/Feline | In-vitro grade; in-vivo grade | Detail |
| pGMoligo486025 | Pre-made Dog/Canine FLT3 siRNA oligo Duplex | 486025 | Dog/Canine | In-vitro grade; in-vivo grade | Detail |
| pGMoligo512700 | Pre-made Bovines/Cattle FLT3 siRNA oligo Duplex | 512700 | Bovines/Cattle | In-vitro grade; in-vivo grade | Detail |
| pGMoligo100061780 | Pre-made Equine/Horse FLT3 siRNA oligo Duplex | 100061780 | Equine/Horse | In-vitro grade; in-vivo grade | Detail |
FLT3/CD135/FLT-3 antibody/GMab
| Cat No. | Species | Antibody Name | Format | Classified by tag | Detail |
|---|
| GM-Tg-hg-T74312-Ab | Human | Anti-Human FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-rg-T74312-Ab | Rat | Anti-Rat FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-mg-T74312-Ab | Mouse | Anti-Mouse FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-cynog-T74312-Ab | Cynomolgus/Rhesus macaque | Anti-Cynomolgus/Rhesus macaque FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-felg-T74312-Ab | Cat/Feline | Anti-Cat/Feline FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-cang-T74312-Ab | Dog/Canine | Anti-Dog/Canine FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-bovg-T74312-Ab | Bovines/Cattle | Anti-Bovines/Cattle FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
| GM-Tg-equg-T74312-Ab | Equine/Horse | Anti-Equine/Horse FLT3/CD135/FLT-3 monoclonal antibody | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
FLT3/CD135/FLT-3 VLP (virus-like particle)/protein
| Cat No. | Species | Antigen Name | Expression Platform | Detail |
|---|
| GM-Tg-hg-T74312-Ag | Human | Human FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-rg-T74312-Ag | Rat | Rat FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-mg-T74312-Ag | Mouse | Mouse FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-cynog-T74312-Ag | Cynomolgus/Rhesus macaque | Cynomolgus/Rhesus macaque FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-felg-T74312-Ag | Cat/Feline | Cat/Feline FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-cang-T74312-Ag | Dog/Canine | Dog/Canine FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-bovg-T74312-Ag | Bovines/Cattle | Bovines/Cattle FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
| GM-Tg-equg-T74312-Ag | Equine/Horse | Equine/Horse FLT3/CD135/FLT-3 VLP (virus-like particle) | HEK293 | Products Developing |
